1.THE METHODS OF MULTIMODALITY IN THE TREATMENT OF 65 CASES OF OSTEOGENIC SARCOMA OF BONE (ANALYSIS REPORT)
Dongyue HU ; Ying XUE ; Xingjun XU
Journal of Xi'an Jiaotong University(Medical Sciences) 1981;0(03):-
Oseteogenic sarcoma is a kind of malignanttumor of bone, it can occur at any age, teenagersare mose commonly involved. The conventionaltreatment of osteogenic sarcoma was high amputa-tion. Although the primary focuses were removedtotaliy, the subclinical minor focuses could not becontrolled effectively. Therefore. the prognosiswas very poor, the five-year survival rate was on-ly about 20 percent. With the rapid development inchemotherapy and orthopedical surgery tech-niques, multimodality therapy of osteogenic sarco-ma were carried out in 65 cases from 1982 to 1988in our hospital. Curative effect has been satisfac-torily improved. The fivc-year survival rate hasbeen raised to 67. 92%. The methods of multi-modality therapy were as follows: ①Peroperationand postoperation chemotherapy with p?liod ofbody. ②Local arteries were perfused with Nitero-gen mustard (HN_2). ③Inactivation of tumor celland replantation. ④Inactivation of tumor cells invivo. ⑤Amputation.
2.Clinical value of serum IL-2,IL-6,IL-10,ChE and HA changes in patients with chronic hepatitis B and liver cirrhosis
Song XU ; Xingjun GU ; Guoqi YANG ; Xiaoxia WANG ; Dachun FAN
International Journal of Laboratory Medicine 2014;(15):1986-1988
Objective To study the changes and clinical significance of serum interleukin-2 (IL-2) ,interleukin-6 (IL-6) ,interleu-kin-10 (IL-10) ,cholinesterase (ChE) and hyaluronic acid (HA) in the patients with chronic hepatitis B (CHB) and liver cirrhosis (LC) .Methods The serum concentrations of IL-2 ,IL-6 ,IL-10 ,ChE and HA were detected in 92 cases of CHB(CHB group) ,63 cases of LC (group LC) and 46 cases of healthy populations (control group) .Results The serum concentrations of IL-2 ,IL-6 and HA in the CHB group and the LC group were higher than those in the control group ,while the serum concentrations of IL-10 and ChE were lower than those in the control group ,the differences had statistical significance (P<0 .05) .The serum concentrations of IL-2 ,IL-6 and HA in the patients with HBV DNA copy number of 6 .0-6 .9 log10 copy/mL were higher than those with the copy number of 3 .0-4 .9 log10 copy/mL and 5 .0 -5 .9 log10 copy/mL ,while the serum concentrations of IL-10 and ChE were lower than those with HBV DNA copy number of 3 .0-4 .9 log10 copy/mL and 5 .0-5 .9 log10 copy/mL ,the differences had statistical significance(P<0 .05) .The serum concentrations of IL-2 ,IL-6 and HA in the LC patients with the Child-Pugh grade C were higher than those with the Child-Pugh grade A and B ,while serum concentrations of IL-10 and ChE were lower than those with the Child-Pugh grade A and B ,the differences were statistically significant (P<0 .05) .Conclusion The simultaneous detection of serum IL-2 ,IL-6 ,IL-10 ,ChE and HA concentration changes can provide certain clinical reference value for the evaluation of severity and prognosis in the patients with CHB and LC .
3.The Research of Low-Field MR Imaging in the Diagnosis of Chondromalacia Patellae
Yongdong WANG ; Jianhong QI ; Min ZHAO ; Jianzhong ZHU ; Rongchun XU ; Xingjun SONG
Journal of Practical Radiology 1996;0(04):-
Objective To evaluate the imaging characteristics of chondromalacia patellae(CMP)in low-field MR and the value of MR in diagnosis.Methods 37 cases with CMP proved by arthroscopy and/or operation were carefully examined by 0.3 Tesla permanent magnet MR unit.The results of MRI were retrospectively analyzed according to that of arthroscopy and operation to search for the MR imaging manifestations of different degrees of patellae cartilage injuries in CMP.Results According to the golden-standard by arthroscopy and operation as for CMP,the overall diagnostic accuracy of MRI was 79.4%,with 28.6% accuracy in the early phase,92.6% in the late phase of CMP.Conclusion Low-field MR imaging is accurate in diagnosing CMP in the late phase and should be suggested as a useful nontraumatic imaging modality in the assessment of CMP before arthroscopy and operation.
4.Related factors in predicting relapse of Graves' disease after treatment with antithyroid drugs
Ling LAN ; Weiping TENG ; Bingyin SHI ; Xingjun LIU ; Hao LI ; Juan LIU ; Xiaoyan WU ; Li XU ; Fangxia WANG
Chinese Journal of Endocrinology and Metabolism 2009;25(3):247-249
Objective To explore the value of thyroid-stimulating antibody(TSAb) and degree of goiter in predicting the outcome of Graves'disease after antithyroid drug treatment. Methods Seventy-one patients with Graves'disease were given antithyroid drugs for (2. 8±1. 4)years and then followed up for(22±6.0)months.Finally,age,gender,thyroid function,TSAb and goiter size at the time of drug withdrawal were compared between the relapsed and relieved groups. TSAb was measured in all patients by using HEK-hTSHR cells. Results Eleven of 71 patients relapsed during the follow-up after drug withdrawal. The relapse rate (42. 9% ,6/14)in patients with positive TSAb was significantly higher than that (8.8%, 5/57) in patient with negative TSAb (X2 = 9.97, P<0.01). The relapse rates in patients with normal size thyroid, Ⅰ degree goiter,Ⅱ degree goiter were 6.25%, 12.2%,35.7% respectively. TSAb activity, positive rate and goiter size of the relapsed patients at the time of drug withdrawal were significantly higher than those of relieved patients (P<0.05 or P<0. 01). Conclusion TSAb activity and goiter size at the time of drug withdrawal are two effective prognostic markers of relapse in Graves' disease treated with antithyroid drugs.
5.Pyruvate substituting lactate dialysis solution peritoneal resuscitation on the effects of hemorrhagic shock rabbit liver function
Xingjun LUO ; Ran RAN ; Heying ZHONG ; Gang TIAN ; Daolin JIAN ; Jie XU
The Journal of Practical Medicine 2017;33(17):2830-2833
Objective To observe the influence of direct peritoneal resuscitation on liver function in hemorrhagic shock rabbits with pyruvate peritoneal dialysis solution instead of lactate peritoneal dialysis solution. Methods 48 hemorrhagic shock rabbits were randomly divided into conventional intravenous resuscitation group (group A),intravenous resuscitation plus intraperitoneal injection of lactate peritoneal dialysis solution group (group B),intravenous resuscitation plus intraperitoneal injection of pyruvate peritoneal dialysis group(group C), intravenous pyruvate peritoneal dialysis resuscitation plus intraperitoneal injection of pyruvate peritoneal dialysis group(group D). The hemodynamic changes were observed and the AST and ALT were measured respectively before and 60 min after shock ,60 min and 180 min after resuscitation. The dry/wet weight ratio ,MDA and SOD of liver tissue were measured,and the liver morphological changes were observed. Results After the completion of shock resuscitation,MAP of all groups were almost restored to the basal level. 180 min after resuscitation,the MAP of animals in group A was lowered than that in group B,C and D(P<0.05). After shock,ALT and AST were signifi-cantly higher than those before shock ,but no significant difference was found between groups (P > 0.05). After resuscitation,ALT and AST continued to decline in all groups,but the decline range increased with the order of A, B,C,D group(P < 0.05). The water content and MDA in liver tissue decreased with the order of A,B,C,D group,while the SOD increased and the differences between groups were significant(P<0.05). And the degree of liver tissue morphological injury also relieved correspondingly. Conclusion Pyruvate substituting lactate peritoneal dialysis solution peritoneal resuscitation can be more effective in reducing liver damage of hemorrhagic shock rabbits.
6.Clinical efficacy and optimal dose of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer
Shile GAO ; Donghui LU ; Meiqin LIU ; Xingjun XU ; Huan MA ; Yu ZHANG
Journal of International Oncology 2022;49(3):140-145
Objective:To explore the clinical efficacy of different doses of apatinib combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) and the adverse reactions.Methods:A total of 69 patients with NSCLC diagnosed in the No. 901 Hospital of the Chinese People′s Liberation Army Joint Logistics Support Force were selected from January 2018 to June 2020, and were divided into chemotherapy alone group (docetaxel+ cisplatin was used), apatinib group A [apatinib (0.25 g)+ docetaxel+ cisplatin was used] and apatinib group B [apatinib (0.50 g)+ docetaxel+ cisplatin was used] according to random number table method, with 23 cases in each group. The objective response rate (ORR), disease control rate (DCR), median overall survival (OS), median progression-free survival (PFS), and incidences of adverse reactions were compared between the three groups of patients.Results:One patients in the apatinib group B withdrew from the study due to acute myocardial infarction. After 4 cycless of treatment, the ORR of the patients in the chemotherapy alone group, apatinib group A and apatinib group B were 17.39% (4/23), 47.83% (11/23) and 54.55% (12/22) respectively, with a statistically significant difference ( χ2=7.41, P=0.024). The ORR of the apatinib group B was higher than that of the chemotherapy alone group, with a statistically significant difference ( χ2=6.77, P=0.009). There were no statistically significant differences in ORR between the apatinib group A and chemotherapy alone group, the apatinib group A and apatinib group B ( χ2=4.85, P=0.028; χ2=0.20, P=0.652). The DCR of the patients in the three groups were 47.83% (11/23), 78.26% (18/23) and 86.36% (19/22) respectively, with a statistically significant difference ( χ2=9.03, P=0.011). The DCR of the apatinib group B was higher than that of the chemotherapy alone group, with a statistically significant difference ( χ2=7.52, P=0.006). There were no statistically significant differences in DCR between the apatinib group A and the chemotherapy alone group, the apatinib group A and apatinib group B ( χ2=4.57, P=0.033; χ2=0.51, P=0.477). The median OS of the patients in the three groups were 6.8, 9.2 and 9.9 months respectively, with a statistically significant different ( χ2=8.91, P=0.022). Compared with the chemotherapy alone group, the median OS of the apatinib group A and apatinib group B were significantly prolonged, with statistically significant differences ( χ2=7.25, P=0.036; χ2=8.60, P=0.029). Compared with the apatinib group A, the median OS of the apatinib group B was prolonged, but there was no statistically significant different ( χ2=1.54, P=0.201). The median PFS of the patients in the three groups were 5.2, 7.7 and 8.2 months respectively, with a statistically significant different ( χ2=8.79, P=0.026). Compared with the chemotherapy alone group, the median PFS of the apatinib group A and apatinib group B were significantly prolonged, with statistically significant differences ( χ2=7.01, P=0.039; χ2=8.36, P=0.031). Compared with the apatinib A group, the median PFS of the apatinib group B was prolonged, but there was no statistically significant different ( χ2=1.68, P=0.186). There were statistically significant differences in the incidences of fatigue [34.78% (8/23) vs. 65.22% (15/23) vs. 72.73% (16/22), χ2=7.50, P=0.024], hypertension [4.35% (1/23) vs. 34.78% (8/23) vs. 68.18% (15/22), χ2=20.07, P<0.001], hand-foot syndrome [4.35% (1/23) vs. 43.48% (10/23) vs. 72.73% (16/22), χ2=22.28, P<0.001] and oral mucositis [8.70% (2/23) vs. 39.13% (9/23) vs. 72.73% (16/22), χ2=19.26, P<0.001] among the three groups. Compared with the chemotherapy alone group, the incidences of hypertension and hand-foot syndrome in the apatinib group A and the incidences of fatigue, hypertension, hand-foot syndrome and oral mucositis in the apatinib group B were increased, with statistically significant differences ( χ2=6.77, P=0.009; χ2=9.68, P=0.002; χ2=6.51, P=0.011; χ2=20.00, P<0.001; χ2=22.37, P<0.001; χ2=19.21, P<0.001). Conclusion:Apatinib (0.50 g) combined with chemotherapy has better short-term efficacy than chemotherapy alone in advanced NSCLC. Apatinib (0.25 g) and apatinib (0.50 g) can prolong the survival of patients, but increasing the treatment dose can not achieve longer survival benefit.
7.Correlation between red blood cell distribution width/platelet count and prognosis of newly diagnosed diffuse large B-cell lymphoma
Xiaobo LIU ; Yanliang BAI ; Ying LIU ; Weiya LI ; Yabin CUI ; Jinhui XU ; Xingjun XIAO ; Xiaona NIU ; Kai SUN
Blood Research 2023;58(4):187-193
Background:
Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and the prognosis of diffuse large B-cell lymphoma (DLBCL).Therefore, this study aimed to investigate the correlation between RPR and the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma.
Methods:
We retrospectively studied 143 patients with newly diagnosed DLBCL and used the median value as the RPR threshold. We also investigated the correlation of pretreatment RPR level with clinical characteristics and its impact on DLBCL prognosis.
Results:
Using the median value as the cut-off, patients with DLBCL were divided into a low RPR group (<0.0549) and a high RPR group (≥0.0549). Patients in the high RPR group were older, had a later Ann Arbor stage, were prone to bone marrow invasion, and had a higher National Comprehensive Cancer Network International Prognostic Index score (P < 0.05). A survival analysis showed that progression-free survival (PFS) (P =0.003) and overall survival (OS) (P <0.0001) were significantly shorter in the high versus low RPR group. A multifactorial Cox analysis showed that bone marrow invasion and elevated lactate dehydrogenase (LDH) were separate risk factors for PFS (P <0.05), while an RPR ≥0.0549 and elevated LDH were separate risk factors for OS (P <0.05).
Conclusion
A high RPR (≥0.0549) in patients with newly diagnosed DLBCL is an independent risk factor for a poor prognosis.
8.Function of AXL and molecular mechanisms in regulation of nasopharyngeal carcinoma.
Kefan ZHOU ; Jin ZHAO ; Hongjuan XU ; Xuejun YAN ; Weidong LIU ; Xingjun JIANG ; Caiping REN
Journal of Central South University(Medical Sciences) 2022;47(6):685-697
OBJECTIVES:
Nasopharyngeal carcinoma (NPC) is a highly invasive epithelial malignant tumor with unique geographical and ethnic distribution characteristics. NPC is mostly found in south China and Southeast Asia, and its treatment mainly depends on radiotherapy and chemotherapy. However, NPC is usually found in the late stage, and local recurrence and distant metastasis are common, leading to poor prognosis. The receptor tyrosine kinase AXL is up-regulated in various tumors and it is involved in tumor proliferation, migration, invasion, and other processes, which are associated with poor prognosis of tumors. This study aims to detect the expression of AXL in NPC cell lines and tissues, and to investigate its biological function of AXL and the underlying molecular mechanisms in regulation of NPC.
METHODS:
The expression levels of AXL in normal nasopharyngeal epithelial tissues and NPC tissues were analyzed by GSE68799, GSE12452, and GSE53819 data sets based on Gene Expression Omnibus (GEO) database. The Cancer Genome Atlas (TCGA) database was used to analyze the relationship between AXL and prognosis of head and neck squamous cell carcinoma (HNSC). The indicators of prognosis included overall survival (OS), disease-free interval (DFI), disease-specific survival (DSS), and progression-free interval (PFI). Western blotting assay was used to detect the AXL protein expression levels in normal nasopharyngeal epithelial cell line and NPC cell lines. Immunohistochemical method was used to detect AXL expression levels in normal nasopharyngeal epithelial tissues and NPC tissues. Cell lines with stable AXL knockdown were established by infecting 5-8F and Fadu cells with lentivirus interference vector, and cell lines with stable AXL overexpression were established by infecting C666-1 and HK-1 cells with lentivirus expression vector. Real-time PCR and Western blotting were used to detect the efficiency of knockdown and overexpression in stable cell lines. The effects of AXL knockdown or overexpression on proliferation, migration, and invasion of NPC cells were detected by CCK-8, plate colony formation, and Transwell assays, and the effect of AXL knockdown on tumor growth in nude mice was detected by subcutaneous tumor formation assay. The sequence of AXL upstream 2.0 kb promoter region was obtained by UCSC online database. The PROMO online database was used to predict AXL transcription factors with 0% fault tolerance, and the JASPAR online database was used to predict the binding sites of ETS1 to AXL. Real-time PCR and Western blotting were used to detect the effect of ETS1 on AXL protein and mRNA expression. The AXL upstream 2.0 kb promoter region was divided into 8 fragments, each of which was 250 bp in length. Primers were designed for 8 fragments. The binding of ETS1 to AXL promoter region was detected by chromatin immuno-precipitation (ChIP) assay to determine the direct regulatory relationship between ETS1 and AXL. Rescue assay was used to determine whether ETS1 affected the proliferation, migration, and invasion of NPC cells through AXL.
RESULTS:
Bioinformatics analysis showed that AXL was highly expressed in NPC tissues (P<0.05), and AXL expression was positively correlated with OS, DFI, DSS, and PFI in HNSC patients. Western blotting and immunohistochemical results showed that AXL was highly expressed in NPC cell lines and tissues compared with the normal nasopharyngeal epithelial cell line and tissues. Real-time PCR and Western blotting results showed that knockdown and overexpression efficiency in the stable cell lines met the requirements of subsequent experiments. The results of CCK-8, plate colony formation, Transwell assays and subcutaneous tumor formation in nude mice showed that down-regulation of AXL significantly inhibited the proliferation, migration, invasion of NPC cells and tumor growth (all P<0.05), and the up-regulation of AXL significantly promoted the proliferation, migration, and invasion of NPC cells (all P<0.05).As predicted by PROMO and JASPAR online databases, ETS1 was a transcription factor of AXL and had multiple binding sites in the AXL promoter region. Real-time PCR and Western blotting results showed that knockdown or overexpression of ETS1 down-regulated or up-regulated AXL protein and mRNA expression levels. ChIP assay result showed that ETS1 bound to AXL promoter region and directly regulate AXL expression. Rescue assay showed that AXL rescued the effects of ETS1 on proliferation, migration and invasion of NPC cells (P<0.05).
CONCLUSIONS
AXL is highly expressed in NPC cell lines and tissues, which can promote the malignant progression of NPC, and its expression is regulated by transcription factor ETS1.
Animals
;
Cell Line, Tumor
;
Cell Movement/genetics*
;
Cell Proliferation/genetics*
;
Gene Expression Regulation, Neoplastic
;
Mice
;
Mice, Nude
;
Nasopharyngeal Carcinoma/genetics*
;
Nasopharyngeal Neoplasms/metabolism*
;
RNA, Messenger/genetics*
;
Sincalide/metabolism*
;
Transcription Factors/genetics*
9.Evaluation of the short-term efficacy and safety of bevacizumab combined with doxorubicin liposomes in the treatment of patients with platinum-resistant recurrent epithelial ovarian cancer
LIU Meiqin ; LU Donghui ; GAO Shile ; XU Xingjun ; ZHANG Yu
Chinese Journal of Cancer Biotherapy 2021;28(8):818-823
[摘 要] 目的:探讨贝伐珠单抗联合多柔比星脂质体治疗铂类耐药复发性卵巢上皮性癌患者的近期疗效和不良反应,并随访生存情况。方法:选取中国人民解放军联勤保障部队第九〇一医院2018年1月至2019年12月收治的76例铂类耐药复发性卵巢上皮性癌患者,采用数字随机分组法分为对照组38例、观察组38例,对照组给予多柔比星脂质体单药化疗4个周期,观察组给予贝伐珠单抗联合多柔比星脂质体化疗4个周期,观察两组患者治疗后近期疗效和不良反应,以及血清肿瘤标志物人附睾蛋白4(human epididymis protein 4,HE4)、糖类抗原125(carbohydrate antigen 125,CA125)变化,并随访总生存期(OS)和无疾病进展生存期(PFS)。结果:对照组患者客观有效率(ORR)为40.54%、疾病控制率(DCR)为67.57%,观察组患者ORR为69.44%、DCR为88.89%,观察组ORR和DCR显著高于对照组(均P<0.05)。治疗后观察组患者血清HE4和CA125分别为(142.67±46.81)pmol/L、(31.79±11.65)U/L,显著低于对照组患者的(219.33±75.67)pmol/L、(57.05±17.85)U/L(均P<0.05)。两组患者的胃肠反应、骨髓抑制、肝肾功能损伤、心脏毒性、过敏反应、血栓栓塞和出血等不良反应相比较差异无统计学意义(均P>0.05);观察组患者高血压发生率显著高于对照组(P<0.05),但可控、可耐受。观察组患者中位OS 和中位PFS分别分别为17.2个月和10.9个月,显著长于对照组患者的14.1个月和7.8个月(均P<0.05)。结论:对于铂类耐药复发性卵巢上皮性癌患者,贝伐珠单抗联合多柔比星脂质体近期疗效可靠、安全性好、不良反应可耐受,值得临床推广。